Eos SENOLYTIX Reports Interim Data Showing Preserved Physical Function with MitoXcel Geropeptide PTC-2105 in a Second Species, Aged-Rat Study
Eos SENOLYTIX reported interim results from an aged-rat study of lead geropeptide PTC-2105 showing preserved Rotarod motor performance (78.4 percentage-point difference vs vehicle, p=0.012) and greater fat-mass loss at Week 8, consistent with prior aged-mouse data. The study is run at Albert Einstein College of Medicine's BIO-VITAL Preclinical Testing Core, with non-GLP tox studies underway to support an IND filing and first-in-human trials targeted for 2027 in sarcopenia.
Key figures
- Drug Name
- PTC-2105
- Phase Of Trial
- Preclinical (IND-enabling)
- First in human target
- 2027
- Oldest cohort enrolled
- 39
- Fat mass reduction week8
- 14.5% vs 8.2% vehicle (12.5 mg/kg, p=0.018)
- Rotarod preservation difference week16
- 78.4 percentage points (p=0.012)
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.